Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03006172
Title To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche

breast cancer

Advanced Solid Tumor


GDC-0077 + Letrozole + Palbociclib


Fulvestrant + GDC-0077

GDC-0077 + Letrozole

Age Groups: adult senior

Additional content available in CKB BOOST